Lecanemab
Infusion that modestly slows early Alzheimer's.
- Starts working
- Varies
- Half-life
- —
- In use since
- 2023
- Pregnancy
- Usually avoided
Overview
Lecanemab is an antibody that clears amyloid plaques and slowed decline by about a quarter over 18 months in early Alzheimer's disease. It requires regular MRI scans because it can cause brain swelling and small bleeds, and is not suitable for everyone.
Conditions it's used for
How it works
Helps the brain's immune system clear sticky amyloid protein.
Lecanemab belongs to the Anti-amyloid antibodies. How Anti-amyloid antibodies work: tag sticky amyloid protein so the brain's immune cells clear it, modestly slowing decline.
Uses
- Early Alzheimer's disease (mild cognitive impairment or mild dementia) with confirmed amyloid
Available as: iv infusion every 2 weeks, subcutaneous autoinjector (maintenance).
Typical dose
- Adults
- 10 mg/kg IV every 2 weeks; maintenance options include less frequent infusions or weekly injections.
Typical doses for orientation only. Your prescription, the pack leaflet and local guidance take priority.
Side effects
Common
Often mild and may settle with time
- Infusion reactions
- Headache
- ARIA on MRI (often without symptoms)
Serious — get medical help
Uncommon, but need prompt attention
- Brain swelling or bleeding (ARIA), higher with two copies of APOE4
- Serious bleeds with blood thinners
Warnings
- Genetic APOE4 testing and MRI before and during treatment
- Generally avoided with anticoagulants
Interactions
- Anticoagulants and thrombolytics — brain bleeding risk
Pregnancy and breastfeeding
Usually avoided
Not studied.
Breastfeeding advice can differ from pregnancy advice — check with a pharmacist, or the LactMed database.
Brand names
- United States
- Leqembi, Leqembi Iqlik
- United Kingdom
- Leqembi
- Europe
- Leqembi
Examples only; many generic versions exist. The same brand name can mean different products in different countries.
History
2023
Accelerated, then full, US approval.
2024
Approved in the UK and, in 2025, the EU — though NHS England did not fund it.
2025
A subcutaneous autoinjector for maintenance approved in the US.
A similar antibody, donanemab (Kisunla), was approved in the US in 2024 and can be stopped once plaques clear.
Common questions
Does it reverse memory loss?
No — it slows the rate of decline in early disease; it doesn't restore lost function.
Do I need a prescription for Lecanemab?
Yes — Lecanemab is prescription-only in most countries.
Can I take Lecanemab during pregnancy?
Usually avoided. Not studied. Always check with a doctor or midwife.
Related medicines
Sources and official information
Entry last reviewed October 2026. Compiled from WHO, NHS, FDA/DailyMed, BNF and national formulary information. How we write entries.